3SBio Inc. is a biotechnology company in the People's Republic of China with research and development, manufacturing, and marketing capabilities focusing on bio-pharmaceutical products. The Company recombinant, or genetically engineered, protein-based products and product candidates are designed to address markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. Its principal products are EPIAO and TPIAO. In addition, it has two legacy products, Intefen and Inleusin; and an in-licensed product, Iron Sucrose Supplement. The Company focuses on its research and development efforts on both novel and validated protein-based therapeutics for the treatment of diseases in the areas of nephrology, oncology, supportive cancer care, inflammation and infectious diseases, and other selected areas. In May 2013, the Company merged with Decade Sunshine Limited and Decade Sunshine Merger Sub.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
Phone+86-24-25811820
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
3SBio (NASDAQ:SSRX) Frequently Asked Questions
What is 3SBio's stock symbol?
3SBio trades on the NASDAQ under the ticker symbol "SSRX."
How were 3SBio's earnings last quarter?
3SBio Inc (NASDAQ:SSRX) issued its earnings results on Monday, March, 18th. The biotechnology company reported $0.12 EPS for the quarter, missing the Zacks' consensus estimate of $0.14 by $0.02. The biotechnology company earned $26.30 million during the quarter, compared to analysts' expectations of $25.63 million. View 3SBio's Earnings History.
Has 3SBio been receiving favorable news coverage?
News articles about SSRX stock have trended somewhat positive this week, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. 3SBio earned a news impact score of 1.2 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
What other stocks do shareholders of 3SBio own?
Who are 3SBio's key executives?
3SBio's management team includes the folowing people:
- Jing Lou, Executive Chairman of the Board, Chief Executive Officer (Age 54)
- Bo Tan, Chief Financial Officer, Executive Vice President, Executive Director (Age 44)
- Fei You, Director - Finance (Age 38)
- Weihonghas Xiao, Chief Operating Officer (Age 48)
- Dongmei Su, Senior Vice President, Executive Director (Age 46)
- Zhenping Zhu MD. Ph.D., Chief Scientific Officer, President - Research & Development (Age 52)
- Bin Huang, Vice President, Executive Director (Age 56)
- Xin Ma, Vice President - Human Resources (Age 51)
- Yongfu Chen, Vice President (Age 60)
- Kevin Liu, Vice President (Age 47)
How do I buy shares of 3SBio?
Shares of SSRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is 3SBio's official website?
How can I contact 3SBio?
3SBio's mailing address is No. 3 A1, Road 10 Shenyang Economy & Technology Development Zone, SHENYANG, LIA 110027, China. The biotechnology company can be reached via phone at +86-24-25811820.
MarketBeat Community Rating for 3SBio (NASDAQ SSRX)
MarketBeat's community ratings are surveys of what our community members think about 3SBio and other stocks. Vote "Outperform" if you believe SSRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SSRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
